Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-04-11

AUTHORS

Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung

ABSTRACT

PurposeThe aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens.MethodsPatients received capecitabine, 2,500 mg/m2/day PO for 14 days (D1–14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0).ResultsForty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1–12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1–12.5%) and the disease control rate was 46.7% (95% CI, 28.6–87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6–16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3–39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%).ConclusionsThe combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer. More... »

PAGES

157-165

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-007-0470-3

DOI

http://dx.doi.org/10.1007/s00280-007-0470-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024757553

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17426971


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily B, Member 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shin", 
        "givenName": "Sang Joon", 
        "id": "sg:person.011321544242.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jeung", 
        "givenName": "Hei-Cheul", 
        "id": "sg:person.01276364570.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ahn", 
        "givenName": "Joong Bae", 
        "id": "sg:person.010673374672.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choi", 
        "givenName": "Hye Jin", 
        "id": "sg:person.01363365111.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cho", 
        "givenName": "Byoung Chul", 
        "id": "sg:person.013035643562.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013035643562.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rha", 
        "givenName": "Sun Young", 
        "id": "sg:person.01036404665.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoo", 
        "givenName": "Nae Choon", 
        "id": "sg:person.01232034433.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232034433.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roh", 
        "givenName": "Jae Kyung", 
        "id": "sg:person.0767622633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "id": "sg:person.016554426212.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1159/000096086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049556297", 
          "https://doi.org/10.1159/000096086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002328609", 
          "https://doi.org/10.1038/sj.bjc.6601724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020964423", 
          "https://doi.org/10.1038/sj.bjc.6602575"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-04-11", 
    "datePublishedReg": "2007-04-11", 
    "description": "PurposeThe aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens.MethodsPatients received capecitabine, 2,500\u00a0mg/m2/day PO for 14\u00a0days (D1\u201314) and doxorubicin, 30\u00a0mg/m2 IV on day 1 every 3\u00a0weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0).ResultsForty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1\u201312) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6\u00a0mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1\u201312.5%) and the disease control rate was 46.7% (95% CI, 28.6\u201387.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3\u00a0weeks (95% CI, 5.6\u201316.7\u00a0weeks). The median overall survival was 29.1\u00a0weeks (95% CI, 18.3\u201339.9\u00a0weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%).ConclusionsThe combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-007-0470-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "61"
      }
    ], 
    "keywords": [
      "gastric cancer", 
      "median progression-free survival", 
      "one-year survival rate", 
      "advanced gastric cancer patients", 
      "prior chemotherapy regimens", 
      "ResultsForty-five patients", 
      "second-line chemotherapy", 
      "third-line chemotherapy", 
      "median dose intensity", 
      "disease control rate", 
      "non-hematologic toxicities", 
      "cycles of chemotherapy", 
      "progression-free survival", 
      "median overall survival", 
      "nausea/vomiting", 
      "hand-foot syndrome", 
      "advanced gastric cancer", 
      "m2/week", 
      "overall response rate", 
      "gastric cancer patients", 
      "doxorubicin combination chemotherapy", 
      "m2 IV", 
      "NCI-CTC", 
      "severe hematologic", 
      "salvage chemotherapy", 
      "salvage regimen", 
      "salvage therapy", 
      "combination regimen", 
      "chemotherapy regimens", 
      "RECIST criteria", 
      "dose intensity", 
      "treat analysis", 
      "overall survival", 
      "combination chemotherapy", 
      "day PO", 
      "cancer patients", 
      "control rate", 
      "disease progression", 
      "capecitabine", 
      "chemotherapy", 
      "day 1", 
      "patients", 
      "response rate", 
      "survival rate", 
      "weeks", 
      "ConclusionsThe combination", 
      "regimen", 
      "doxorubicin", 
      "cancer", 
      "survival", 
      "toxicity", 
      "MethodsPatients", 
      "vomiting", 
      "neutropenia", 
      "regimens", 
      "anemia", 
      "hematologic", 
      "syndrome", 
      "therapy", 
      "progression", 
      "rate", 
      "total", 
      "days", 
      "safety", 
      "aim", 
      "response", 
      "activity", 
      "criteria", 
      "study", 
      "intent", 
      "PO", 
      "combination", 
      "analysis", 
      "cycle", 
      "intensity"
    ], 
    "name": "Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer", 
    "pagination": "157-165", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024757553"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-007-0470-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17426971"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-007-0470-3", 
      "https://app.dimensions.ai/details/publication/pub.1024757553"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_445.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-007-0470-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0470-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0470-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0470-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0470-3'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      22 PREDICATES      124 URIs      113 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-007-0470-3 schema:about N3cf6134675664df280798714786562d2
2 N3f31a7047f374b399e5b7ed5ae647c15
3 N451a0aed370d40c082e67979717042f1
4 N581d661baa704399831e7b4a32ca384c
5 N5b5fd6173ea14cf1b915d00c99ec1043
6 N6f723c69b28f450f921972a583689ede
7 N7951cbdf838340e0bd1c03f433d1bc7f
8 N7ac3a08823274c0291c9f1a0792a15fe
9 N7e2e05c5120c4fd3af093f5f56d7f0d0
10 N88d19941bd9a4425afe601347905e9b5
11 N9b2031d69563451fbf5be5ea007e88c6
12 Naa320fc2c8f5417a832fbcbb99569d4e
13 Nac0694ec26c343359066cd7338d5f900
14 Nb3303b5b10a342e784c92f469f236c96
15 Nbf8a858f7d5e49f0af4f39b0ee323d9c
16 Nc644bac34d134a03a8a0e9981f8d43c9
17 Nc7fb7cba451a450c9e92c4b2076f7ec0
18 Ndb069b82376945f59b26bfcaf1eadebd
19 Neb8b644e5baa48c8b2c6aa51a535f7e2
20 Nf53057ea75284e958d1c85f0d4916d80
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author Ne83a8434c7b14a04941f0b44609a85d7
24 schema:citation sg:pub.10.1038/sj.bjc.6601724
25 sg:pub.10.1038/sj.bjc.6602575
26 sg:pub.10.1159/000096086
27 schema:datePublished 2007-04-11
28 schema:datePublishedReg 2007-04-11
29 schema:description PurposeThe aim of this study was to evaluate the activity and the safety of a combination regimen of capecitabine and doxorubicin as salvage chemotherapy in advanced gastric cancer patients who had undergone one or two prior chemotherapy regimens.MethodsPatients received capecitabine, 2,500 mg/m2/day PO for 14 days (D1–14) and doxorubicin, 30 mg/m2 IV on day 1 every 3 weeks until disease progression. The response was evaluated according to RECIST criteria, and the toxicity was evaluated by NCI-CTC (version 2.0).ResultsForty-five patients were enrolled. Twenty-six patients were treated as second-line chemotherapy and the remaining patients as third-line chemotherapy. A total of 152 cycles of chemotherapy (median 2, range 1–12) were administered. Median dose intensities of capecitabine and doxorubicin were 11,326 and 9.6 mg/m2/week, respectively. The overall response rate was 6.7% (95% CI, 4.1–12.5%) and the disease control rate was 46.7% (95% CI, 28.6–87.1%) according to an intent-to-treat analysis. The median progression-free survival was 11.3 weeks (95% CI, 5.6–16.7 weeks). The median overall survival was 29.1 weeks (95% CI, 18.3–39.9 weeks) with one-year survival rate of 24%. Severe (grade III/IV) hematologic and non-hematologic toxicity was uncommon and included nausea/vomiting in five (11.1%), neutropenia in two (4.4%), anemia in one (2.2%), and hand-foot syndrome in one patient (2.2%).ConclusionsThe combination of capecitabine and doxorubicin is a feasible salvage regimen in advanced pre-treated gastric cancer.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N1687a3fd0e5a4f74ac46255f2d6904e3
34 N68f053f8c1054d8fa0213e305715773d
35 sg:journal.1088364
36 schema:keywords ConclusionsThe combination
37 MethodsPatients
38 NCI-CTC
39 PO
40 RECIST criteria
41 ResultsForty-five patients
42 activity
43 advanced gastric cancer
44 advanced gastric cancer patients
45 aim
46 analysis
47 anemia
48 cancer
49 cancer patients
50 capecitabine
51 chemotherapy
52 chemotherapy regimens
53 combination
54 combination chemotherapy
55 combination regimen
56 control rate
57 criteria
58 cycle
59 cycles of chemotherapy
60 day 1
61 day PO
62 days
63 disease control rate
64 disease progression
65 dose intensity
66 doxorubicin
67 doxorubicin combination chemotherapy
68 gastric cancer
69 gastric cancer patients
70 hand-foot syndrome
71 hematologic
72 intensity
73 intent
74 m2 IV
75 m2/week
76 median dose intensity
77 median overall survival
78 median progression-free survival
79 nausea/vomiting
80 neutropenia
81 non-hematologic toxicities
82 one-year survival rate
83 overall response rate
84 overall survival
85 patients
86 prior chemotherapy regimens
87 progression
88 progression-free survival
89 rate
90 regimen
91 regimens
92 response
93 response rate
94 safety
95 salvage chemotherapy
96 salvage regimen
97 salvage therapy
98 second-line chemotherapy
99 severe hematologic
100 study
101 survival
102 survival rate
103 syndrome
104 therapy
105 third-line chemotherapy
106 total
107 toxicity
108 treat analysis
109 vomiting
110 weeks
111 schema:name Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
112 schema:pagination 157-165
113 schema:productId N13a3bc43682244eabf6695d2239eefb9
114 Nc2d2929d702541f2966bda418154bd0e
115 Ne879e0cb99d940ce9936096e6656ea89
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024757553
117 https://doi.org/10.1007/s00280-007-0470-3
118 schema:sdDatePublished 2022-05-20T07:24
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N2f1541911cba4ea780863d719a6a9001
121 schema:url https://doi.org/10.1007/s00280-007-0470-3
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N04ac4bec8adb48e0a3fe9343f7b7b1d6 rdf:first sg:person.013035643562.16
126 rdf:rest Nba25391744a2404284a7001bd09f7baa
127 N08680fe829b04bdca6bee7a10bbace6b rdf:first sg:person.01232034433.81
128 rdf:rest N40964ee7d87e45ce8ec39b633dbf56fa
129 N13a3bc43682244eabf6695d2239eefb9 schema:name doi
130 schema:value 10.1007/s00280-007-0470-3
131 rdf:type schema:PropertyValue
132 N1687a3fd0e5a4f74ac46255f2d6904e3 schema:volumeNumber 61
133 rdf:type schema:PublicationVolume
134 N254d6070a0024b36aeddfbf25496bea9 rdf:first sg:person.01363365111.85
135 rdf:rest N04ac4bec8adb48e0a3fe9343f7b7b1d6
136 N2f1541911cba4ea780863d719a6a9001 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N3cf6134675664df280798714786562d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 N3f31a7047f374b399e5b7ed5ae647c15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Stomach Neoplasms
143 rdf:type schema:DefinedTerm
144 N40964ee7d87e45ce8ec39b633dbf56fa rdf:first sg:person.0767622633.82
145 rdf:rest N5cdde0ae42cd450f9c8c1a247d8897ab
146 N451a0aed370d40c082e67979717042f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Deoxycytidine
148 rdf:type schema:DefinedTerm
149 N581d661baa704399831e7b4a32ca384c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Fluorouracil
151 rdf:type schema:DefinedTerm
152 N5b5fd6173ea14cf1b915d00c99ec1043 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Doxorubicin
154 rdf:type schema:DefinedTerm
155 N5cdde0ae42cd450f9c8c1a247d8897ab rdf:first sg:person.016554426212.74
156 rdf:rest rdf:nil
157 N68f053f8c1054d8fa0213e305715773d schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 N6f723c69b28f450f921972a583689ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Capecitabine
161 rdf:type schema:DefinedTerm
162 N7951cbdf838340e0bd1c03f433d1bc7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Dose-Response Relationship, Drug
164 rdf:type schema:DefinedTerm
165 N7ac3a08823274c0291c9f1a0792a15fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Drug Resistance, Multiple
167 rdf:type schema:DefinedTerm
168 N7e2e05c5120c4fd3af093f5f56d7f0d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name ATP Binding Cassette Transporter, Subfamily B, Member 1
170 rdf:type schema:DefinedTerm
171 N88d19941bd9a4425afe601347905e9b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Adult
173 rdf:type schema:DefinedTerm
174 N8adc62fed57f400d865b046833106b5e rdf:first sg:person.010673374672.49
175 rdf:rest N254d6070a0024b36aeddfbf25496bea9
176 N9b2031d69563451fbf5be5ea007e88c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Aged
178 rdf:type schema:DefinedTerm
179 Naa320fc2c8f5417a832fbcbb99569d4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Drug Resistance, Neoplasm
181 rdf:type schema:DefinedTerm
182 Nac0694ec26c343359066cd7338d5f900 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Salvage Therapy
184 rdf:type schema:DefinedTerm
185 Nb3303b5b10a342e784c92f469f236c96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Humans
187 rdf:type schema:DefinedTerm
188 Nba25391744a2404284a7001bd09f7baa rdf:first sg:person.01036404665.54
189 rdf:rest N08680fe829b04bdca6bee7a10bbace6b
190 Nbf8a858f7d5e49f0af4f39b0ee323d9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Disease-Free Survival
192 rdf:type schema:DefinedTerm
193 Nc2d2929d702541f2966bda418154bd0e schema:name dimensions_id
194 schema:value pub.1024757553
195 rdf:type schema:PropertyValue
196 Nc644bac34d134a03a8a0e9981f8d43c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Survival Rate
198 rdf:type schema:DefinedTerm
199 Nc7fb7cba451a450c9e92c4b2076f7ec0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Male
201 rdf:type schema:DefinedTerm
202 Ndb069b82376945f59b26bfcaf1eadebd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Middle Aged
204 rdf:type schema:DefinedTerm
205 Nde8ef3029a5244548a0627449599e24c rdf:first sg:person.01276364570.14
206 rdf:rest N8adc62fed57f400d865b046833106b5e
207 Ne83a8434c7b14a04941f0b44609a85d7 rdf:first sg:person.011321544242.27
208 rdf:rest Nde8ef3029a5244548a0627449599e24c
209 Ne879e0cb99d940ce9936096e6656ea89 schema:name pubmed_id
210 schema:value 17426971
211 rdf:type schema:PropertyValue
212 Neb8b644e5baa48c8b2c6aa51a535f7e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Antineoplastic Combined Chemotherapy Protocols
214 rdf:type schema:DefinedTerm
215 Nf53057ea75284e958d1c85f0d4916d80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Disease Progression
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
222 schema:name Oncology and Carcinogenesis
223 rdf:type schema:DefinedTerm
224 sg:journal.1088364 schema:issn 0344-5704
225 1432-0843
226 schema:name Cancer Chemotherapy and Pharmacology
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01036404665.54 schema:affiliation grid-institutes:grid.15444.30
230 schema:familyName Rha
231 schema:givenName Sun Young
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54
233 rdf:type schema:Person
234 sg:person.010673374672.49 schema:affiliation grid-institutes:grid.15444.30
235 schema:familyName Ahn
236 schema:givenName Joong Bae
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49
238 rdf:type schema:Person
239 sg:person.011321544242.27 schema:affiliation grid-institutes:grid.15444.30
240 schema:familyName Shin
241 schema:givenName Sang Joon
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27
243 rdf:type schema:Person
244 sg:person.01232034433.81 schema:affiliation grid-institutes:grid.15444.30
245 schema:familyName Yoo
246 schema:givenName Nae Choon
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232034433.81
248 rdf:type schema:Person
249 sg:person.01276364570.14 schema:affiliation grid-institutes:grid.15444.30
250 schema:familyName Jeung
251 schema:givenName Hei-Cheul
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14
253 rdf:type schema:Person
254 sg:person.013035643562.16 schema:affiliation grid-institutes:grid.15444.30
255 schema:familyName Cho
256 schema:givenName Byoung Chul
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013035643562.16
258 rdf:type schema:Person
259 sg:person.01363365111.85 schema:affiliation grid-institutes:grid.15444.30
260 schema:familyName Choi
261 schema:givenName Hye Jin
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85
263 rdf:type schema:Person
264 sg:person.016554426212.74 schema:affiliation grid-institutes:grid.15444.30
265 schema:familyName Chung
266 schema:givenName Hyun Cheol
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
268 rdf:type schema:Person
269 sg:person.0767622633.82 schema:affiliation grid-institutes:grid.15444.30
270 schema:familyName Roh
271 schema:givenName Jae Kyung
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82
273 rdf:type schema:Person
274 sg:pub.10.1038/sj.bjc.6601724 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002328609
275 https://doi.org/10.1038/sj.bjc.6601724
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/sj.bjc.6602575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020964423
278 https://doi.org/10.1038/sj.bjc.6602575
279 rdf:type schema:CreativeWork
280 sg:pub.10.1159/000096086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049556297
281 https://doi.org/10.1159/000096086
282 rdf:type schema:CreativeWork
283 grid-institutes:grid.15444.30 schema:alternateName Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea
284 schema:name Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, CPO Box #8044, 120-752, Seoul, South Korea
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...